A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers

Study summary

To compare the difference of a marker of cellular proliferation in all bronchial biopsy specimens of former smokers stratified by lung cancer risk, collected before and after treatment per patient between the enzastaurin and placebo groups.

Ask AI to explain this study

Start here

Key things to know

Main goalPrevention

This describes the study’s primary purpose.

What is being studiedEnzastaurin and Placebo

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 21, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Eli Lilly and Company

Study sponsor

Study overview

What this study is about

Purpose: Prevention
Study type: Interventional
Phase: Phase 2
Sponsor: Eli Lilly and Company
Interventions being studied: Drug: Enzastaurin; Drug: Placebo

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Sputum atypia participants with normal sputum cytology will be removed from the study)
Metaplasia or dysplasia on at least one bronchoscopy specimen
History of cigarette smoking ≥30 Pack Years
Quit smoking ≥1 year prior to study entry
Able to undergo bronchoscopy and helical computed tomography (CT) scanning of the chest
Able to swallow tablets

Reasons someone may not be able to joinExclusion criteria

Blood clotting abnormalities
Current smoking within the past 1 year
Unwillingness to abstain from smoking while enrolled in the clinical trial or unwillingness to avoid significant second hand smoke exposure
Evidence for lung cancer or carcinoma in situ
Active cardiovascular disease
Current illicit drug or alcohol abuse

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.Tampa, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 21, 2020. Always confirm current availability with the study team.

View original record ↗